Unadjusted comparisons of induction cisplatin and capecitabine ( PX ) versus adjuvant PF indicated a favorable trend in progression-free survival for the conventional fractionation arm ( P = .045 ) ; analyses that were adjusted for other significant factors and fractionation reflected a significant reduction in the hazards of disease progression ( hazard ratio [ HR ] , 0.54 ; 95 % confidence interval [ CI ] , 0.36-0 .80 ) and death ( HR , 0.42 ; 95 % CI , 0.25-0 .70 ) .